Condition 1: Non alcoholic fatty liver disease. Condition 2: Fatty liver disease. Non-alcoholic fatty liver disease Non-alcoholic fatty liver disease, unspecified
Conditions
Interventions
Intervention 1: Intervention group receive 3 capsules daily containing whole powder of Ganoderma lucidum, 220 mg
pure aqueous extract of Ganoderma lucidum, 30 mg standardized based on 17 micrograms per 1 mg total, produced by Ki Daroo Technology Company, the Ministry of Health license code 1681449932720180. It i
Sponsors
Semnan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patient refered to gastroentrology clinic of semnan kosar hospital Diagnose is Non alcoholic fatty liver disease Don't receive treatment yet
Exclusion criteria
Exclusion criteria: No sonographic change for fatty liver Alcoholic fatty liver Other liver disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effects of Ganoderma lucidum on ALT in Non alcoholic fatty liver disease patient. Timepoint: 12 week. Method of measurement: Laboratory Reference.;Effects of Ganoderma lucidum on AST in Non alcoholic fatty liver disease patient. Timepoint: 12 week. Method of measurement: laboratory Reference. | — |
Secondary
| Measure | Time frame |
|---|---|
| CHOLESTROL. Timepoint: 12 week. Method of measurement: Laboratory reference.;LDL. Timepoint: 12week. Method of measurement: Laboratory reference.;HDL. Timepoint: 12 week. Method of measurement: Laboratory reference. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHanif Hashemnejad
Semnan University of Medical Sciences
Outcome results
None listed